Menu Search
Equities

N4 Pharma PLC

0GO:FRA

N4 Pharma PLC

Actions
  • Price (EUR)0.001
  • Today's Change0.00 / 0.00%
  • Shares traded3.00k
  • 1 Year change-85.71%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.

  • Revenue in GBP (TTM)5.86k
  • Net income in GBP-1.12m
  • Incorporated1979
  • Employees5.00
  • Location
    N4 Pharma PLCWeston House, 1 Bradgate Park ViewDERBY DE73 5UJUnited KingdomGBR
  • Phone+44 133 269 0061
  • Fax+44 127 982 1300
  • Websitehttps://www.n4pharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.